Patent application number | Description | Published |
20080206313 | COMPOSITIONS USEFUL ESPECIALLY FOR TREATMENT OR PREVENTION OF METABOLIC SYNDROME - This invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual, wherein an effective amount of an amine oxidase enzyme inhibitor is administered to said individual. In addition, the invention relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual, wherein a vitamin B1, its derivative, its precursor or metabolite is administered to said individual. Finally, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier. | 08-28-2008 |
20080213176 | Compositions for Targeting Amine Oxidases in Vivo - This invention relates to a diagnostic compositions for targeting an amine oxidase enzyme in vivo, said composition comprising a labelled peptide having the capability to bind to said enzyme. Further, the invention concerns a pharmaceutical composition for use to modulate the activity of an amine oxidase enzyme, said composition comprising a peptide having the capability to bind to said enzyme, wherein said peptide further is conjugated to a therapeutically active agent. Still further, the invention concerns a novel peptide and its uses, especially as VAP-1 inhibitor. | 09-04-2008 |
20080267958 | Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof - A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial cells. CLEVER-1 is the first protein that has been reported to mediate both influx into and efflux from the lymph nodes. Also provided are methods of treating inflammation and preventing metastasis of malignant cells by providing an inhibitor of CLEVER-1 binding. | 10-30-2008 |
20100209942 | NEW BIOMARKER FOR MONITORING DEVELOPMENT OF DISEASES AND ASSESSING THE EFFICACY OF THERAPIES - The invention concerns a method for monitoring the development of a disease in a patient, or for assessing the efficacy of a cytokine therapy or a statin therapy in a patient, in which methods CD73 in a tissue fluid drawn from said patient is used as a biomarker. The invention concerns also methods for determining of CD73 protein in a sample drawn from an individual's tissue fluid. | 08-19-2010 |
20100310579 | METHOD FOR INHIBITING ANGIOGENESIS OR FOR TREATMENT OF CANCER - The invention concerns a method for inhibiting angiogenesis or for treating or preventing cancer or cancer metastasis in an individual. The method is based on the administration of an agent capable of counteracting the influence of or for down-regulating the expression of the vascular adhesion protein 1 (VAP-I). The inhibition of the catalytic activity of VAP-I is especially desirable for inhibiting angiogenesis and for treating or preventing of cancer or cancer metastasis. | 12-09-2010 |
20110038922 | COMPOUNDS FOR TREATING OR PREVENTING AMINE OXIDASE RELATED DISEASES OR DISORDERS - This invention relates to small interfering RNAs (siRNAs) that down regulates the expression of vascular adhesion protein 1 (VAP-1) for prevention or treatment of a disease or disorder that benefits from the inhibition or down regulation of VAP-1. Pharmaceutical compositions comprising said siRNAs in combination with pharmaceutically acceptable carriers are also included. Furthermore, the invention concerns expression vectors comprising nucleic acids encoding the siRNA duplexes or the antisense strands of said duplexes in a manner which allows expression of said siRNA duplexes or antisense strands within a mammalian cell. Pharmaceutical compositions comprising said expression vectors in combination with pharmaceutically acceptable carriers are also included. | 02-17-2011 |
20120027770 | NOVEL CELL AND THERAPEUTICAL AND DIAGNOSTICAL METHODS BASED THEREON - The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman. | 02-02-2012 |
20120115815 | COMPOSITIONS USEFUL ESPECIALLY FOR TREATMENT OR PREVENTION OF METABOLIC SYNDROME - This invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual, wherein an effective amount of an amine oxidase enzyme inhibitor is administered to said individual. In addition, the invention relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual, wherein a vitamin B1, its derivative, its precursor or metabolite is administered to said individual. Finally, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier. | 05-10-2012 |
20130217033 | BIOMARKER FOR MONITORING DEVELOPMENT OF DISEASES AND ASSESSING THE EFFICACY OF THERAPIES - The invention concerns a method for monitoring the development of a disease in a patient, and for assessing the efficacy of a therapy influencing on the CD73 level or activity in the patient, in particular a cytokine therapy or a statin therapy. CD73 in a tissue fluid drawn from the patient is used as a biomarker. The invention concerns also methods for determining of CD73 protein in a sample drawn from an individual's tissue fluid. | 08-22-2013 |
20140294760 | NOVEL CELL AND THERAPEUTICAL AND DIAGNOSTICAL METHODS BASED THEREON - The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman. | 10-02-2014 |